Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond

Chim, C S, Kumar, S K, Orlowski, R Z, Cook, G, Richardson, P G, Gertz, M A, Giralt, S, Mateos, M V, Leleu, X, Anderson, K C·2018·Leukemia
DOI 10.1038/leu.2017.329

Cited by (305)

Items 301–305 of 305

  1. Etude de la kinase PIM2 dans la différenciation terminale normale et tumorale des lymphocytes B en plasmocytes
    Marion Haas · 2023 · theses.fr (ABES)
  2. Decoding immunotherapy resistance in multiple myeloma: genetic insights and approaches to counter resistance
    Huan Li, Qi Xia, Mengke Yu, Ying Lv, Jialing Xiao, Xiaoxin Guo, Kai Dong, Yu Zhou, Ling Zhong, Tingting Wang et al. · 2026 · Science China Life Sciences
  3. Innate immune dysregulation in multiple myeloma: molecular basis and mechanistic interventions
    Gang Wang, Hanlin Gao, Tianyi Xie, Fuming Zi · 2026 · International Immunopharmacology
  4. NHE6-driven endosome-autophagy axis confers proteasome inhibitor resistance in multiple myeloma
    Liuting Chen, Feifei Cheng, Yung-Hsing Huang, Yutong Wang, Jin He, Jiaqi Liu, Zhiming Wang, Pei Lin, Yihui Fan, Li Bao et al. · 2026 · Drug Resistance Updates
  5. The proteasomal switch as a kinetic battleground for influenza A virus pathogenesis
    Sourabh Soni, Vandana Anang, Pankaj Kumar, Anteneh Mehari Tizazu, Eldana G Arega, Richard Seonghun Nho, Ana Lucia Mora, Mauricio Rojas, Jing Zhao, Yutong Zhao et al. · 2026 · Emerging Microbes & Infections